A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
Inclusion Criteria:
Exclusion Criteria:
Everett, California 98208, United States
Washington D.C., District of Columbia 20010, United States
Saint Louis Park, Minnesota 55416, United States
EAST Bentleigh, Victoria VIC 3165, Australia
Vienna, 1090, Austria
Beijing, 100071, China
Shanghai, 200025, China
Wuhan, 430022, China
Medellin-Antioquia, Colombia
Saint Prient En Jarez, 42271, France
Frankfurt am Main, 60389, Germany
Homburg/Saar, 66424, Germany
Lichtenberg, 10367, Germany
Villingen-Schwenningen, 78052, Germany
Szeged, 6701, Hungary
Legnago, Lombardy 37045, Italy
Ehime, 791-0280, Japan
Gunma, 371-8511, Japan
Kanagawa, 216-8511, Japan
Campehe, Campeche 24096, Mexico
Montrrey, Nuevo León 64710, Mexico
Quezon City, Luzon, 1101, Philippines
Gda?sk, 80-214, Poland
Wieliszew, 05-135, Poland
Moscow, Moscow Oblast 115478, Russia
Pyatigorsk, Stavropol Kray 357502, Russia
Kazan', Tatarstan Republic 420029, Russia
Stavropol, 355045, Russia
Sabadell, Barcelona, Barcelona 08208, Spain
A Coruña, LA Coruna 15006, Spain
Santiago de Compostela, LA Coruna 15706, Spain
A Coruña, 15009, Spain
Kiev, 03115, Ukraine
Berkshire, RG1 5AN, United Kingdom